News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneron Pharmaceuticals, Inc. (REGN),Sanofi (France) (SAN.PA)'s Cholesterol Drug Investigated By FDA For Side Effects



3/10/2014 7:53:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Regeneron Pharmaceuticals Inc. (REGN:US) and Sanofi (SAN) and must assess how their experimental cholesterol drug affects brain function after U.S. regulators learned of adverse events associated with this new class of medicines.

The companies don’t know how the Food and Drug Administration learned of the side effect, Paris-based Sanofi said today in a regulatory filing. Sanofi, Regeneron and Amgen Inc. (AMGN:US) are among companies in late-stage testing of the therapies, which are designed to inhibit the PCSK9 protein associated with high levels of LDL, or “bad” cholesterol.

Help employers find you! Check out all the jobs and post your resume.

Read at Business Week
Read at Wall Street Journal
Read at Reuters
Read at Forbes
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES